Sarcopenia and inflammation are independent predictors of survival in male patients newly diagnosed with small cell lung cancer
- 7 November 2015
- journal article
- Published by Springer Science and Business Media LLC in Supportive Care in Cancer
- Vol. 24 (5), 2075-2084
- https://doi.org/10.1007/s00520-015-2997-x
Abstract
Sarcopenia is suggested to be associated with cancer-related inflammation. We assessed the clinical outcome of small cell lung cancer (SCLC) patients according to sarcopenia and the neutrophil-to-lymphocyte ratio (NLR). A total of 117 male SCLC patients treated with first-line chemo- or chemoradiotherapy were assessed based on a retrospective chart review. The mass of the pectoralis muscle was measured by computed tomography and normalized to height. Patients with the lowest quartile of muscle mass were considered to have sarcopenia. Patients were classified into four groups according to their sarcopenia and NLR statuses: sarcopenia/high NLR, sarcopenia/low NLR, non-sarcopenia/high NLR, and non-sarcopenia/low NLR. Sarcopenic patients had lower progression-free survival (PFS) than did non-sarcopenic patients (median 6.0 vs. 7.5 months, p = 0.009), but the difference in overall survival (OS) was not statistically significant (median 10.5 vs. 13.5 months, p = 0.052). However, the OS of sarcopenic patients with high NLR was significantly lower than that in all other groups (median 3.2 vs. 16.0 vs. 12.5 vs. 13.7 months, respectively, p < 0.001), as was PFS (median 3.2 vs. 7.7 vs. 7.6 vs. 7.1 months, respectively, p < 0.001). On multivariate analysis, sarcopenia with high NLR was an independent prognostic factor for shorter PFS and OS. Early discontinuation of treatment (20.0 vs. 10.3 %) and treatment-related mortality (50.0 vs. 8.4 %) occurred more frequently in these patients than in the other groups (p < 0.001). In SCLC, sarcopenic male patients with high NLR have a poor prognosis and do not tolerate standard treatment. Intensive supportive care is needed in these patients.Keywords
This publication has 37 references indexed in Scilit:
- Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular CarcinomaPLOS ONE, 2012
- Definition and classification of cancer cachexia: an international consensusThe Lancet Oncology, 2011
- Oxidative Stress, Molecular Inflammation and SarcopeniaInternational Journal of Molecular Sciences, 2010
- Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinomaAnnals Of Oncology, 2010
- Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine TreatmentClinical Cancer Research, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Interleukin-6 and cachexia inApcMin/+miceAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2008
- Body Composition as an Independent Determinant of 5-Fluorouracil–Based Chemotherapy ToxicityClinical Cancer Research, 2007
- Age-related differences in skeletal muscle protein synthesis: relation to markers of immune activationAmerican Journal of Physiology-Endocrinology and Metabolism, 2005
- An approach to the management of unintentional weight loss in elderly peopleCMAJ : Canadian Medical Association Journal, 2005